 | • レポートコード：MRC2303I0235 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、131ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の動物用疼痛管理市場規模が、予測期間中に年平均6.2%で成長すると予測しています。本書では、動物用疼痛管理の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（医薬品、デバイス）分析、用途別（変形性関節症・関節痛、術後疼痛、がん、その他）分析、動物種類別（コンパニオンアニマル、家畜動物）分析、エンドユーザー別（病院・診療所、小売店及びその他）分析、地域別（北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ、アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、その他）分析、競争状況、市場機会・将来の動向など、以下の構成でまとめております。また、Assisi Animal Health、Boehringer Ingelheim International GmbH、Ceva Sante Animale、Chanelle Veterinary Limited、Dechra Pharmaceuticals PLC、Elanco Animal Health Incorporated、Norbrook、VetoquinolSA、Zoetis Inc.、Merck and Co Inc.、Eltech K-Laser SRLなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の動物用疼痛管理市場規模：製品別 - 医薬品における市場規模 - デバイスにおける市場規模 ・世界の動物用疼痛管理市場規模：用途別 - 変形性関節症・関節痛における市場規模 - 術後疼痛における市場規模 - がんにおける市場規模 - その他用途における市場規模 ・世界の動物用疼痛管理市場規模：動物種類別 - コンパニオンアニマルにおける市場規模 - 家畜動物における市場規模 ・世界の動物用疼痛管理市場規模：エンドユーザー別 - 病院・診療所における市場規模 - 小売店及びその他エンドユーザーにおける市場規模 ・世界の動物用疼痛管理市場規模：地域別 - 北米の動物用疼痛管理市場規模 アメリカの動物用疼痛管理市場規模 カナダの動物用疼痛管理市場規模 メキシコの動物用疼痛管理市場規模 … - ヨーロッパの動物用疼痛管理市場規模 ドイツの動物用疼痛管理市場規模 イギリスの動物用疼痛管理市場規模 フランスの動物用疼痛管理市場規模 … - アジア太平洋の動物用疼痛管理市場規模 中国の動物用疼痛管理市場規模 インドの動物用疼痛管理市場規模 日本の動物用疼痛管理市場規模 … - 中東・アフリカの動物用疼痛管理市場規模 GCC諸国の動物用疼痛管理市場規模 南アフリカの動物用疼痛管理市場規模 … - 南米の動物用疼痛管理市場規模 ブラジルの動物用疼痛管理市場規模 アルゼンチンの動物用疼痛管理市場規模 … - その他地域の動物用疼痛管理市場規模 ・競争状況 ・市場機会・将来の動向 |
The veterinary pain management market is expected to register a CAGR of 6.2% over the forecast period.
The global outbreak of COVID-19 impacted the veterinary pain management market, adversely affecting the supply chain of veterinary products. For instance, in April 2020, the Food Agriculture Organization published a new policy regarding the production of livestock and the supply chain of livestock products during the pandemic, which slowed down the supply of veterinary products. However, the high adoption rate of pet animals during the lockdown increased the demand for veterinary pain management drugs. For instance, according to the PDSA PAW report published in June 2021, 2.0 million people in the United Kingdom adopted pets between March 2020 to May 2021. Therefore, owing to such factors, the market has started to gain momentum and is expected to maintain an upward trend over the forecast period.
The growth in the prevalence of painful and inflammatory diseases in animals, the rise in the need for easily accessible and affordable treatment options, and the increase in awareness about animal health and welfare are the major drivers of the market. For instance, according to an article published by Morris Animal Foundation in March 2021, osteoarthritis affects around 14.0 million adult dogs in the United States every year, and owners have consistently reported it as a top health concern among pets. Similarly, according to an article published by American Animal Health Association in April 2021, approximately 6.0 million dogs are diagnosed with cancer each year. The same source also stated that around one in four dogs would develop cancer at some point, and nearly 50.0% of dogs older than ten would develop some form of cancer.
Per the report published by the CDC in September 2021, Bovine Spongiform Encephalopathy (BSE) is one of the most prevalent chronic diseases among cattle in Canada. The report stated that the true prevalence of Bovine Spongiform Encephalopathy (BSE) in Canada was around 90.0%, which is higher than the prevalence of BSE in the United States (3.0 to 8.0 cases per million in Canada and around 0.167 cases per million in the United States). Such a high prevalence of diseases is anticipated to propel the demand for veterinary pain management drugs, thereby boosting the market’s growth.
Rising initiatives by the government and other organizations are also expected to positively impact the market. For instance, in October 2020, FECAVA launched a campaign titled “FECAVA Basic Practices in Anesthesia and Analgesia,” which includes important lectures around Europe in the upcoming years and a series of six ready-to-use, printable posters/infographics regarding anesthesia and pain management in animals. Such supportive initiatives are expected to create new opportunities for the market in the coming years.
New product launches by the key players in the market are also expected to propel the market’s growth. For instance, in January 2022, the US FDA approved Zorbium (buprenorphine transdermal solution), the first transdermal buprenorphine animal medication for post-surgical pain management in cats. This approval provides veterinarians with another option for controlling postoperative pain in cats. Thus, owing to such factors, considerable market growth is anticipated over the forecast period.
However, side effects associated with treatment and the high cost of certain products are likely to impede the market growth over the forecast period.
Veterinary Pain Management Market Trends
Laser Therapy is Expected to Witness Considerable Growth Over the Forecast Period
Laser therapy is used for chronic and acute injuries, arthritis, sprains and strains, swelling due to back disc problems, and muscular-skeletal abnormalities. It also helps to regenerate nerve tissue post-surgery. The most common laser therapy is the therapeutic laser treatment of osteoarthritis (OA) in dogs and cats. The laser intensity in osteoarthritis (OA) is most appropriate: 8-10 J/cm2. Tendonitis may also benefit from laser therapy due to the inflammation associated with the disease.
Some laser devices can be used both for surgical and therapeutic purposes by controlling the level of emission. Some of the laser therapy brands for veterinary pain management include B-Cure Laser, TENDLITE, Lumasoothe, iReliev, Keebomed, and MLS Laser Therapy (ASAveterinary), among others.
Market players adopt and implement various strategies, such as product launches, collaborations, expansions, and mergers. For instance, in October 2021, Summus Laser introduced ‘’Horizon Veterinary Laser System,’’ a Class IV laser therapy system designed specifically for veterinary pain management. It is a diode-based laser with 28-watt power and has the unique capability of combining four different wavelengths, which can be controlled independently as well. Therefore, owing to the aforementioned factors, the segment is expected to witness considerable growth over the forecast period.
North America is Expected to Witness Significant Growth Over the Forecast Period
North America is expected to dominate the overall veterinary pain management market over the forecast period. The growth is due to factors such as rising pet adoption and the increasing per capita animal healthcare expenditure in the region. The rise in the prevalence of various animal diseases and injuries has been identified as the major factor fueling the market’s growth.
According to the American Pet Products Association’s 2021-2022 National Pet Owners Survey, around 69.0 million Americans own a dog, 45.3 million own cats, 11.8 own freshwater fish, 9.9 million own birds, 6.2 million own small animals, 5.7 million own reptiles, 3.5 million own horses, and 2.9 million own saltwater fish. With the increased ownership of pets and livestock, US citizens have also become more considerate toward the health of these animals. As per the data provided by America Veterinary Medical Association, in March 2020, approximately USD 29.3 billion was spent in the country on veterinary care and services. Thus, with the increased awareness and expenditure regarding animal health, the market is expected to show significant growth over the forecast period in North America.
The rising partnerships/agreements, mergers, and acquisitions between companies are fueling the market growth in the United States. Many companies are launching new products in the market. For instance, in 2020, the US FDA approved Cronus Pharma Specialties’ Carprofen Chewable Tablets (generic version of Rimadyl—Zoetis) for dogs. This nonsteroidal anti-inflammatory drug (NSAID) has been proven safe and effective in relieving pain and inflammation associated with osteoarthritis. Furthermore, it helps control postoperative pain associated with soft tissue and orthopedic surgeries.
Hence, owing to the factors mentioned above, along with the rising prevalence of inflammatory diseases in animals, the veterinary pain management market is expected to grow over the forecast period.
Veterinary Pain Management Market Competitor Analysis
The veterinary pain management market is moderately competitive, with the presence of both international and local companies. The competitive landscape includes an analysis of a few international as well as local companies that hold market shares and are well known, including Ceva Sante Animale, Elanco Animal Health Incorporated, Zoetis Inc., Vetoquinol SA, and Boehringer Ingelheim International GmbH.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definitions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growth in Prevalence of Painful and Inflammatory Diseases in Animals
4.2.2 Rise in Need for Easily Accessible and Affordable Treatment Options
4.2.3 Increase in Awareness about Animal Health and Welfare
4.3 Market Restraints
4.3.1 Side Effects Associated With Treatment and High Cost of Certain Products
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Product
5.1.1 Drugs
5.1.1.1 NSAIDs
5.1.1.2 Anesthetics
5.1.1.3 Opioids
5.1.1.4 Other Drugs
5.1.2 Devices
5.1.2.1 Laser Therapy
5.1.2.2 Electromagnetic Therapy
5.2 By Application
5.2.1 Osteoarthritis and Joint Pain
5.2.2 Postoperative Pain
5.2.3 Cancer
5.2.4 Other Applications
5.3 By Animal Type
5.3.1 Companion
5.3.2 Livestock
5.4 By End User
5.4.1 Hospitals and Clinics
5.4.2 Retail Outlet and Others
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Assisi Animal Health
6.1.2 Boehringer Ingelheim International GmbH
6.1.3 Ceva Sante Animale
6.1.4 Chanelle Veterinary Limited
6.1.5 Dechra Pharmaceuticals PLC
6.1.6 Elanco Animal Health Incorporated
6.1.7 Norbrook
6.1.8 VetoquinolSA
6.1.9 Zoetis Inc.
6.1.10 Merck and Co Inc.
6.1.11 Eltech K-Laser SRL
7 MARKET OPPORTUNITIES AND FUTURE TRENDS